

## Press Release

Stockholm, April 23, 2026

**Intervacc brings together leading US and European experts to jointly tackle strangles**  
Today, Intervacc AB (publ), a Swedish growth company specialising in animal vaccines, together with Dechra Pharmaceuticals PLC, is hosting a European Key Opinion Leader (KOL) meeting focused on advancing best practice in the prevention and control of strangles.

The KOL meeting is held over two days and brings together leading equine veterinarians, researchers and industry experts from across US and Europe. It forms part of Intervacc's and Dechra's ongoing efforts to support education, scientific dialogue and collaboration within the equine community, with the long-term objective of reducing the impact of strangles.

### **The purpose of the meeting**

Strangles remains one of the most contagious and disruptive infectious diseases affecting horses worldwide, with significant consequences for animal welfare, equestrian businesses and the wider industry. The purpose of the KOL meeting is to facilitate expert level scientific and clinical discussion on how strangles can be most effectively managed, with a particular emphasis on evidence-based prevention strategies.

Over the course of the meeting, participants will engage in structured sessions covering key topics including vaccine safety, real-world efficacy, use of vaccination during outbreaks, management of high risk populations, persistently infected carriers, and the development of practical guidelines for veterinarians and horse owners. The programme combines scientific data review, case-based experience and roundtable discussions to encourage open exchange and consensus building.

### **Ensuring diverse perspectives**

The meeting hosts a broad panel of internationally recognised Key Opinion Leaders in equine medicine, representing academia, clinical practice, animal welfare organisations and professional bodies. Experts attending represent a wide range of countries, ensuring diverse perspectives shaped by different epidemiological and practical contexts.

*"Strangles continues to represent a major challenge for equine health and welfare globally," says Carl-Johan Dalsgaard, CEO of Intervacc. "By bringing together leading experts with extensive scientific and clinical experience, we aim to strengthen the shared understanding of how strangles can be best prevented and managed in real-world settings. This KOL meeting underscores our long-term commitment to collaboration, evidence-based guidance and close partnership with the veterinary community."*

Andrew Waller CSO Intervacc adds: *"By bringing together veterinarians and researchers with hands-on experience from different countries and equine sectors, this meeting creates an important platform for exchanging practical insights that can support veterinarians in tackling this challenging disease."*

### **The final goal of the meeting**

*"Our goal in bringing together the Western world's leading experts in animal healthcare is to develop a common direction and joint effort to reduce the number of outbreaks and, in the long-term, eradicate strangles completely", concludes Carl-Johan Dalsgaard.*

The KOL-meeting takes place on 23–24 April 2026 at Norton House, Edinburgh, Scotland.

## Press Release

Stockholm, April 23, 2026

**For more information please contact:**

Carl-Johan Dalsgaard, CEO

Phone: +46 (0)8 120 10 600

E-mail: [carl-johan.dalsgaard@intervacc.se](mailto:carl-johan.dalsgaard@intervacc.se)

*The information was submitted for publication, through the agency of the contact person set out above on April 23, 2026 at 08.30 CET.*

**About Strangvac**

Strangvac® is a vaccine against the severe disease equine strangles. The vaccine is approved for sales and marketing in the EU as well as the UK, Iceland, Norway and Liechtenstein, and has been launched in Sweden, Denmark, Finland, the UK, France, Germany, Belgium, the Netherlands, Austria, Spain, Portugal, Ireland, Poland, Slovenia and Italy.

**About Intervacc**

Intervacc AB is an animal health group that develops vaccines for animals. The company's vaccines and vaccine candidates are based on many years of research at the Karolinska Institute and the Swedish University of Agricultural Sciences. The Intervacc share (Nasdaq: IVACC) is listed on the Nasdaq First North Growth Market. For more information, see [intervacc.se](http://intervacc.se)

**Contact information for Certified Adviser**

Eminova Fondkommission AB

E-mail: [adviser@eminova.se](mailto:adviser@eminova.se), Phone: +46 (0)8 – 684 211 10